Prof. Joshi is the Vice President for Research and Innovation and Stokes Professor of GlycoSciences at University of Galway, Ireland.

His primary research interest is in the roles played by complex sugars in biological systems and technologies to study and understand these roles in maintaining health and during disease processes. His laboratory is developing technologies for high-throughput biomimic discovery and microarray based glycomics studies for clinical and industrial applications including infectious and chronic diseases and biopharmaceuticals.

Prof. Joshi hasa PhD in Biological Sciences and Biochemistry from Bath University, UK, where he worked on the strategies adopted by pathogenic fungi to colonize the host. He thencompleted Post-Doctoral and Research Associate experience in molecular fungal pathology and glycobiology at Cornell University, Ithaca, New York. He was appointed Research Assistant Professor in the School of Life Sciences at Arizona State University in 2000 and joined the Department of Bioengineering and the Biodesign Institute as an Associate Professor in 2003 where he led a team of researchers working on the glycosylation pathway discovery and engineering and peptide therapeutics to produce biomolecules of therapeutic value. During this period, Prof. Joshi, along with two colleagues, also co-founded a successful biotechnology start-up, Arizona Engineered Therapeutics (AzERx). In 2005, he was appointed as the Director of the Center for Glycosciences and Technology in the Biodesign Institute at Arizona State University.

Prof. Joshi relocated to Ireland in 2007 as Stokes Professor of Glycosciences and Bristol-Myers Squibb Professor at the National Center for Biomedical Engineering Science at National University of Ireland Galway (now University of Galway). He was appointed the Associate Director of Center for BioAnalytical Sciences funded with 10M by BMS and Industrial Development Agency (IDA) Ireland. In 2009,a team led by Prof. Joshi was awarded with 5.2M grant by Science Foundation Ireland to establish Alimentary Glycoscience Research Cluster (AGRC) with the objectives of understanding the role of glycosylation in host-microbial interactions in the gut. In 2010, Prof. Joshi andcolleagues won a 3M European Union grant to establish an international research consortium (GlycoHIT) to develop the next generation of glycobiomimic and glycosensor tools for the diagnosis of cancer glycobiomarkers in patient serum.

Prof. Joshi was appointed the Vice President for Research at National University of Ireland Galway in January 2013 and in this capacity, he leads the Office for the Vice President for Research responsible for sustaining and growing research, innovation and entrepreneurship across the University.

Prof. Joshi is the founder of Aquila Bioscience, a life sciences company developing innovative and nature-inspired technologies for the protection from pathogens. Aquila Bioscience has received funding support from the European Defence Agency, EU, European Innovation Council and the European Space Agency.

PRINCIPAL AREAS OF RESEARCH. My principal focus of research is integration of life sciences, chemistry, engineering, medicine and informatics in the field of Glycosciences to discover and develop novel molecules and relevant technologies for industrial and clinical purposes. The research group is developing technologies that are amenable for HTP methods. These Technologies are being applied to host-pathogen biology, stem cell, cancer, apoptosis, immunology and biopharmaceutical manufacturing processes.

My lab is also developing tools to explore the applications of bioinformatics and data science to glycosciences with an aim to understand the impact of glycosylation related changes on physiology.

Prof. Joshi teaches undergraduate and post-graduate classes on glycosciences, protein technologies, clinical and industrial applications, innovation, impact and entrepreneurship.